Form 8-K NEUROCRINE BIOSCIENCES For: Feb 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Neurocrine Bio. (NBIX) PT Lowered to $179 at BofA Securities
February 7, 2025 6:08 AM ESTBofA Securities analyst Tazeen Ahmad lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $179.00 (from $184.00) while maintaining a Buy rating.
The analyst comments "NBIX announced FY24 Ingrezza revenues of $2.31bn (+26% y/y, ours: $2.316bn, cons: $2.32bn). On FY25 outlook, the company guided to FY25 sales of... More
